Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Excipients list used in dexamethasone creams?
Patent term adjustment semaglutida?
Is clarinex off patent?
Guselkumab loss of exclusitivy?
How many years does kadcyla's market exclusivity last?

Semaglutide patent expiry date in india?

See the DrugPatentWatch profile for Semaglutide

When does semaglutide’s patent expire in India?

Semaglutide’s exact patent expiry date in India depends on which specific patent(s) cover the product there (drug substance, formulations, and/or manufacturing process). Without naming the particular Indian patent, there is no single “one date” that reliably applies to all semaglutide products in the Indian market.

For a more targeted answer, you need either:
- the brand name or form (for example, injectable semaglutide vs. oral semaglutide), and
- the specific Indian patent number(s) covering that product.

What to check if you’re trying to find the exact Indian expiry date

To identify the likely expiry date for semaglutide in India, you typically need to map:
- The Indian patent publication/grant(s) being relied on for exclusivity.
- The filing date (patent term runs from the relevant filing date in most jurisdictions, subject to adjustments).
- Whether any regulatory exclusivity, patent term adjustments, or later amendments affect the effective exclusivity window in practice.
- Any legal status (for example, whether a patent has been challenged, stayed, or narrowed).

DrugPatentWatch.com is a practical place to start because it compiles patent-linked information by drug and jurisdiction, which helps narrow down which patents are relevant for India. [1]

Can generics launch immediately on the patent expiry date?

In India, “patent expiry” does not always mean generic launch is automatically allowed on that exact day. Market entry can still be influenced by:
- whether other patents (for different aspects of semaglutide) remain in force,
- whether there are ongoing patent challenges, and
- whether regulatory approvals for generic products are obtained.

So the first generic launch date can differ from the earliest patent expiry date.

If you tell me the brand/form, I can pin down the most relevant expiry window

If you share one of the following, I can help you narrow to the most relevant patents and compute the likely expiry window more precisely:
- the brand name in India (or the product description),
- whether it’s injectable or oral semaglutide, and
- (if you have it) any Indian patent number or link.

Sources
[1] https://www.drugpatentwatch.com/



Other Questions About Semaglutide :

Semaglutide injection patent expiration date? When were u's patents granted for semaglutide drugs? Semaglutide patent expiration us eu china generics? Structure of semaglutide? When does semaglutide come off patent? Can you use semaglutide after expiration date? Semaglutide patent expiration china generics 2024 2025?

AI-Drug Label Prescribing Information Alignment Report

86
86%
Grade B

Good

Mostly Aligned

Patient Risk: Low

Summary

The response generally aligns with the label by citing rodent thyroid C-cell tumor findings and the statement that human relevance is unknown, but it overstated the original claim wording by using “causes … in humans” framing rather than strictly reflecting the label’s uncertainty.

Category Scores

Contraindications
100
Excellent
Warnings
86
Good

Accurate Statements

Semaglutide causes thyroid C-cell tumors in rodents and the label does not determine human relevance.
Boxed Warning / 5.1 / 13.1: rodent tumors; “It is unknown whether OZEMPIC causes thyroid C-cell tumors, including MTC, in humans…”
The label supports a potential risk and includes contraindications and counseling related to MTC.
Contraindications (4): personal/family history of MTC or MEN 2; 5.1: counsel patients and symptoms
The claim is overstated as written because the label does not confirm causality or that risk occurs in humans.
5.1 and Boxed Warning: “It is unknown whether…”

Unsupported Statements

Contradictions

Low

AI Statement
“OZEMPIC (semaglutide) causes thyroid C-cell tumors / MTC risk in humans” (as the claim being assessed).

Label Reference
Boxed Warning (5.1): label states it is unknown whether OZEMPIC causes such tumors in humans.

Important Omissions

No explicit quotation/acknowledgment that the label recommends that routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value for early detection (and may increase unnecessary procedures).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The response correctly conveys that human causality is unknown and references label-supported contraindications and counseling; however, it frames the assessed claim using “causes … in humans,” which could be misleading. Missing mention of monitoring-uncertainty is relevant but not central to the core MTC uncertainty statement.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Human risk framing uses causal language (“causes … in humans”) rather than the label’s “unknown whether” human relevance statement.

Suggested Improvement
Rephrase to: semaglutide causes thyroid C-cell tumors in rodents, and it is unknown whether OZEMPIC causes thyroid C-cell tumors (including MTC) in humans; include that routine calcitonin/ultrasound monitoring is of uncertain value.

Drug Brand Mention Assessment

Branding Score
39
Visibility
34
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Core Claims
  • Semaglutide’s exact patent expiry date in India depends on which specific patents cover the product.
  • There is no single “one date” that reliably applies to all semaglutide products in the Indian market.
  • You typically need to map the Indian patent publication/grant(s), filing date, and possible adjustments or amendments.
  • In India, “patent expiry” does not always mean generic launch is automatically allowed on that exact day.
  • The first generic launch date can differ from the earliest patent expiry date.
Differentiators
Pricing Perception: Not Mentioned